Series: The Heart Scare That Almost Killed TRT
Subtitle: How a 2010 study, a flawed meta-analysis, and a media panic nearly derailed testosterone therapy for a generation
Post: 5 of 5
Tags: TRT, TRAVERSE, cardiovascular monitoring, hypogonadism, FDA indications, evidence-based medicine, prostate safety
Word Count: ~1,150
The TRAVERSE trial answered the question that had been hanging over testosterone therapy since 2010 with the specificity and rigor the question deserved. In 5,246 men with hypogonadism and meaningful cardiovascular risk, followed for nearly three years, testosterone gel did not increase the rate of major adverse cardiovascular events relative to placebo.
That is the settled part.
The unsettled parts are worth being honest about, because the history of this field suggests that overclaiming in either direction eventually generates another round of alarm, another policy overcorrection, and another decade of patients caught in the middle while experts debate.
What Is Now Settled
The acute cardiovascular risk question — does testosterone therapy cause heart attacks and strokes in men with hypogonadism? — has been answered as definitively as clinical trials can answer things.
For men with documented hypogonadism (testosterone below 300 ng/dL on two morning measurements) and no recent acute cardiovascular events, the TRAVERSE data provides high-quality evidence that appropriately dosed testosterone therapy does not meaningfully increase MACE risk relative to placebo over a roughly three-year treatment horizon.
This is not a niche finding. TRAVERSE was a 5,000-person randomized controlled trial designed and powered specifically to address this question. Its primary endpoint was pre-specified. The outcome adjudication was blinded and independent. The result was published in the New England Journal of Medicine — the same journal that effectively anchored the cardiovascular safety concerns of the previous decade.
The FDA’s subsequent update to testosterone prescribing language reflected this evidence. The aggressive warning language added in 2014, when the only available data was the compromised Vigen observational study, has been substantially revised to reflect what the randomized evidence actually shows.
What Is Still Open
Long-term effects in younger men. TRAVERSE enrolled men aged 45–80 with preexisting cardiovascular risk factors. It does not speak to what happens over 20 or 30 years in men who start TRT in their 30s or 40s, with healthier baseline cardiovascular profiles. The three-year follow-up is adequate for demonstrating the absence of acute risk, but the field genuinely does not know what lifelong physiologic testosterone replacement looks like in terms of decade-scale outcomes. More data is needed, and intellectual honesty requires saying so.
Atrial fibrillation. TRAVERSE found a statistically significant increase in new-onset atrial fibrillation in the testosterone group (3.5% vs. 2.4%). The absolute risk difference is small, and the clinical significance in an otherwise healthy population remains debated. But AF is not a trivial finding — it is associated with stroke risk and requires monitoring. Current guidelines recommend periodic cardiac rhythm assessment in men on long-term TRT, particularly those with other AF risk factors.
Hematocrit and polycythemia. Testosterone reliably increases red blood cell production. TRAVERSE confirmed an elevated rate of polycythemia in the testosterone group. Elevated hematocrit increases blood viscosity and can theoretically increase clotting risk. Monitoring hematocrit — generally at baseline, 3–6 months into therapy, and annually thereafter — is a standard part of responsible TRT management.
Prostate safety. TRAVERSE found higher rates of prostate biopsy and prostate cancer diagnosis in the testosterone group. The absolute numbers were small and the clinical significance of many of those diagnoses (predominantly low-grade disease) is debated in a field where overdiagnosis of low-grade prostate cancer is itself a recognized problem. But the finding reinforces that PSA monitoring remains standard of care for men on TRT. The question of whether testosterone therapy causes clinically meaningful prostate cancer acceleration — as opposed to simply triggering detection of cancers that were already present — remains an active area of research.
Recent cardiac events. TRAVERSE excluded men who had experienced a myocardial infarction or stroke in the previous six months. The question of TRT safety in men who have recently had a cardiac event is not answered by this trial, and the standard clinical approach is to defer TRT initiation until the patient has stabilized and the cardiovascular picture has been reassessed.
The Regulatory Landscape Today
The FDA-approved indication for testosterone products technically remains hypogonadism due to an associated medical condition — meaning primary hypogonadism (testicular failure from genetic, anatomic, or iatrogenic causes) or secondary hypogonadism resulting from specific hypothalamic or pituitary pathology.
The language around “age-related decline” remains in a regulatory gray zone. The FDA’s position, consistent since 2014, is that testosterone products are not approved for the treatment of low testosterone levels that are a consequence of normal aging in the absence of an underlying medical cause.
In clinical practice, this distinction is frequently navigated by clinicians who recognize that the symptoms of hypogonadism — fatigue, low libido, impaired concentration, mood disturbance, decreased muscle mass, increased adiposity — are real and documented regardless of their etiology. Many clinicians treat symptomatic men with two confirmed low testosterone measurements and appropriate clinical evaluation, with ongoing monitoring, regardless of whether a specific organic cause has been identified. The Endocrine Society’s 2018 clinical practice guidelines, while recommending treatment for men with classical hypogonadism, also acknowledge the complexity of the clinical presentation in men with age-related decline.
What Men on TRT Should Know About Cardiac Monitoring
For men currently on testosterone therapy or considering starting:
Baseline testing matters. Before initiating TRT, a responsible prescribing protocol includes two morning testosterone measurements, a comprehensive metabolic panel, a CBC (to establish baseline hematocrit), a PSA measurement, and a clinical cardiovascular risk assessment. This is not bureaucratic box-checking — it establishes the baseline against which subsequent monitoring is compared.
Monitoring frequency. Standard monitoring during TRT includes hematocrit at 3–6 months (and annually), PSA at 3–6 months (and annually), and testosterone levels to confirm that doses are achieving physiologic targets rather than supraphysiologic levels.
The dose-response relationship. TRAVERSE used testosterone gel titrated to keep testosterone in the 350–750 ng/dL range. The concerning findings in the 2010 Basaria trial involved, in some men, supraphysiologic dosing. Physiologic replacement — aiming for the middle of the normal male range — is both effective and appears safe based on current evidence. Supraphysiologic dosing is a separate category with separate risk considerations.
TRT is a medical treatment, not a lifestyle supplement. The TRAVERSE data is reassuring. It is not a green light for unsupervised, unmonitored testosterone use at any dose. The beneficial safety profile in the trial was in the context of supervised, titrated dosing with structured follow-up.
The View From Here
The story of TRT and cardiovascular risk is, at its core, a story about how medicine processes uncertainty. A small stopped trial generated a signal. That signal was amplified by a flawed observational study. A regulatory warning was issued. Prescribing patterns changed. Men who might have benefited from treatment were undertreated for a decade.
Then someone ran a proper trial.
The proper trial showed that the worst-case feared scenario — testosterone as a broad cardiovascular threat — was not what the evidence supported. The signal from 2010 was a real but narrow finding in an extremely high-risk population, not a generalizable verdict.
Science worked. It just took thirteen years and 5,246 patients to get there. Which is, depending on your perspective, either a reasonable amount of time to establish the safety of a widely used medication, or a long time for thousands of symptomatic men to go undertreated while the argument played out.
This concludes Series 5: “The Heart Scare That Almost Killed TRT."
Up next — Series 6: “The Obesity-Testosterone Death Spiral: Why carrying extra weight tanks your testosterone, and why low testosterone makes you gain more weight — the cycle that nobody warned men about.”
